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Objectives: Drug resistant Mycobacterium tuberculosis causes much higher rates of treatment 
toxicity, failure or relapse, and mortality. We determined the drug resistant profile of 
Mycobacterium tuberculosis strains isolated from a population of HIV-infected patients in 
southern Brazil and studied the potential factors associated with resistance.
Methods: We conducted a retrospective cohort study to determine the resistance profile 
of Mycobacterium tuberculosis isolated from HIV-infected patients and factors that could be 
associated with resistance from 2000 to 2005. 
Results: 236 patients were included in the study. Resistance to at least one drug was observed 
in 32 (14.6%) isolates, and multi-drug resistance was observed in 4 (1.82%) isolates. On 
multivariate analysis, previous use of tuberculostatics and quinolones were related to any 
first-line drug resistance.
Conclusions: In our study, previous quinolone use was significantly associated to first-line 
anti-TB drugs resistance. Multi-drug-resistant tuberculosis (MDR-TB) is a major problem 
worldwide, and we believe quinolones should be used with caution in settings where TB is 
endemic.
Introduction
Tuberculosis (TB) and human immunodeficiency virus (HIV) 
disease are the two leading causes of infectious disease-
associated mortality worldwide.1 According to the World 
Health Organization (WHO) report — published on World TB 
Day, March 24, 2009 — there were an estimated 9.27 million 
new cases of tuberculosis worldwide in 2007, and 1.37 million 
cases in HIV-infected persons.2 
Resistance to antituberculosis drugs was first described 
soon after the introduction of streptomycin in 1944, and 
is currently one of the most important threats to global 
tuberculosis control.3 Drug resistance causes much higher 
rates of treatment toxicity, costs, failure, and mortality.4 
Co-infection with HIV has been associated with TB drug-
resistance.5
Because of the poor data available and in order to 
detect changes in the patterns of resistance, this study 
was performed to determine the resistance profile 
of Mycobacterium tuberculosis isolated from a population of 
HIV-infected patients and factors associated with resistance 
in southern Brazil.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Methods
A retrospective cohort study was performed at Hospital 
de Clínicas de Porto Alegre, a 735-bed tertiary care 
hospital in southern Brazil. From August 2000 to August 
2005, all consecutive hospitalized HIV-infected patients 
with positive culture from any clinical specimens for 
Mycobacterium tuberculosis detected in the laboratory of 
microbiology were included.
Patient records were reviewed. Previous use of 
antituberculosis drugs was defined as any anti-TB treatment 
started before hospitalization. Previous use of quinolones 
was defined as the use of this medication for at least five 
days, in the six-month period before hospital arrival. Primary 
resistance was defined as resistance in isolates from patients 
who did not have history of TB treatment. The following 
variables were studied: gender, age, diagnostic infection site, 
length of time for Mycobacterium tuberculosis identification 
in specimens’ culture, and TB-drugs susceptibility profile. 
We also reviewed CD4 lymphocyte count and HIV viral 
load tests performed within six months of hospitalization. 
Primary outcome was defined as hospital discharge or 
in-hospital death. Any drug resistance was defined as 
resistance to rifampin, isoniazid, pirazinamide, ethambutol, 
or streptomycin.
Mycobacterial identification and resistance profile 
were assessed according to hospital routine. Specimens 
from anatomic sites where normal bacterial flora were 
present were submitted to digestion with the mucolytic 
agent 5% N-acetyl-L-cysteine and to decontamination 
with 2% sodium hydroxide using the BBL MycoPrep kit 
(Becton Dickinson, Sparks, MD – USA) in 50 mL screw-
cap polypropylene tubes. These samples were further 
concentrated by centrifugation (3,000 rpm for 15 min). 
Specimens from sterile sites were concentrated directly 
by centrifugation as above. A volume of 1 mL of the 
concentrated sample was used to inoculate l iquid 
MiddleBrook medium (Bactec 12B with Bactec supplement, 
PANTA), which was processed by the radiometric method 
(Bactec 460TB System, Becton Dickinson) for culture of 
Mycobacterium spp. In parallel, a volume of 0.2 mL of the 
concentrated sample was also processed for conventional 
Mycobacterium  spp. culture using Lowenstein-Jensen 
medium. The identification of TB complex was performed 
using the p-nitro-acetyl-amino-hydroxypropiophenone 
(NAP) test in the Bactec System (Becton Dickinson). Cultures 
positive for the TB complex were submitted to susceptibility 
tests for isoniazid (INH), rifampin (RIF), ethambutol (EMB) 
and streptomycin (SM), using the radiometric method 
(Bactec System). The susceptibility test for pyrazinamide 
(PZA) was carried out on a modified culture medium 
with pH set to 6.0 (Bactec, PZA). The TB strain H37Rv 
(susceptible to the five drugs tested) was used as a quality 
control to certify the activity of the first-line anti-TB 
agents. Mycobacterium bovis BCG (clinical strain identified 
at the Professor Hélio Fraga National Reference Center for 
Tuberculosis, Brazil) was used as a quality assurance of 
PZA resistance.
Pearson’s chi-square and Fisher’s exact test were used to 
evaluate the association between qualitative variables. Mann-
Whitney’s test was used to compare continuous data when 
normality of data could not be assured. Poisson regression 
multivariate analysis was performed including the following 
variables: previous use of RIF, INH, PZA, SM, EMB, previous 
use of tuberculostatics and previous use of quinolones. Two-
tail level of significance was of 5%, and data analysis was 
performed on the Statistical Package for the Social Sciences 
(SPSS) version 16.0 software.
Results
The patients’ characteristics are shown in Table 1. A total of 
285 patients were included; 49 were initially excluded because 
of age under 18 or negative test for HIV infection or were not 
tested for HIV infection. 
Data from resistance profile were available from 219 
patient isolates (92.7%). Resistance to any drug was observed 
in 14.6% of patient isolates (n = 32). Four isolates (1.82%) 
were resistant to rifampin, 17 (7.76%) were resistant to 
isoniazid, seven (3.19%) were resistant to pyrazinamide, 
16 (7.3%) were resistant to streptomycin and three (1.36%) were 
resistant to ethambutol. Multi-drug resistant (i.e. resistance 
to isoniazid and rifampin) TB was observed in four (1.82%) 
patient specimens. 28 patients with resistant isolates (87.5%) 
were considered as having primary resistance. 
All patients n = 236
Age – median, interquartile range (years) 33 (27-39)
Men [% (n)] 64.4 (152)
CD4 – median, interquartile range (cels/µL);  
n = 141
84 (38-172)
Viral load – median, interquartile  
range (log/mL); n = 50
4.88 (3.96-5.39)
Site of infection [% (n)]
 Pulmonary
 Disseminated*
 Lymph nodes
 Pleural
 CNS
 Others**
52.5 (124)
25.4 (60)
11.4 (27)
4.7 (11)
3.4 (8)
2.6 (6)
Median time to TB therapy –  
interquartile range (days); n = 228***
1 (0-7)
Outcome [% (N)]
 In-hospital death
 Discharge
33.5 (79)
66.5 (157)
*Defined as infection in two non-contiguous sites, or identification 
of Mycobacterium tuberculosis in blood, bone marrow or liver;  
**urinary tract, pericardial, joints, mediastinal mass, abscesses, 
bone; ***time in days counted from sample collection to therapy 
initiation.
Table 1 - Demographic characteristics of patients
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Age 
 
Gender 
 
Quinolone 
 
Days  
of use 
Days from 
therapy to 
culture1
Date of 
culture  
Indication  
of use 
Any drug 
resistance2 
Outcome 
 
Patient 1 21 F Levofloxacin 11 30 04-oct-00 Respiratory 
infection
No Discharge
Patient 2 31 M Ciprofloxacin 7 45 03-feb-01 Respiratory 
infection
Yes Death
Patient 3 34 M Levofloxacin 8 133 25-may-01 Respiratory 
infection
No Discharge
Patient 4 19 M Levofloxacin 5 9 03-aug-01 Respiratory 
infection
Yes Discharge
Patient 5 60 M Ciprofloxacin, 
levofloxacin
5 30 19-oct-01 Respiratory 
infection
No Discharge
Patient 6 27 F Ciprofloxacin 13 71 13-dec-01 Presumed  
NTM infection
No Death
Patient 7 39 F Levofloxacin 5 29 03-may-02 Respiratory 
infection
Yes Death
Patient 8 31 F Levofloxacin, 
ciprofloxacin
12 
2
13 23-apr-02 Respiratory  
infection
No Death
Patient 9 43 M Gatifloxacin > 5 < 6 months 04-sep-02 Respiratory 
infection
No Discharge
Patient 10 40 F Levofloxacin 10 10 31-oct-02 Respiratory 
infection
No Discharge
Patient 11 27 F Levofloxacin 10 17 26-dec-02 Respiratory 
infection
Yes Discharge
Patient 12 34 M Levofloxacin 5 29 06-mar-03 Respiratory 
infection
Yes Death
Patient 13 33 M Ciprofloxacin, 
levofloxacin
3 
7
14 29-mar-04 Diarrhea 
Respiratory 
infection
No Death
Patient 14 29 F Levofloxacin 7 < 6 months 28-sep-04 Respiratory 
infection
No Death
Patient 15 33 F Levofloxacin 6 < 6 months 26-jul-05 Respiratory 
infection
No Discharge
NTM, non-tuberculous mycobacteria; 1days from therapy to culture, means the number of days from quinolone therapy initiation to date of 
culture collection; 2any drug resistance, means resistance to rifampin, isoniazid, pirazinamide, ethambutol or streptomycin.
Table 2 - Characteristics of patients with tuberculosis previously exposed with quinolones
In our analysis we included isolates from clinical specimens 
of different sites for the same patient with a positive culture 
showing resistance to any tuberculostatic drug. Resistance 
to any drug was more common in specimens from central 
nervous system TB (34.4%, n = 10), when compared to lymph 
nodes (17.6%, n = 18; p = 0.05), disseminated disease (16.8%, 
n = 16; p = 0.04), and respiratory tract (12.5%, n = 21, p < 0.01).
As shown in Table 2, 15 patients (6,84%) had previously used 
quinolones. On univariate analysis, prior quinolone treatment 
was associated with resistance to rifampin (OR 16.54; 95% 
CI 2.15-125.21; p < 0.01), to isoniazid (OR 3.94; 95% CI 1.02-
15.79; p = 0.04), to streptomycin (OR 4.3; 95% CI 1.04-17.73; 
p = 0.02), to ethambutol (OR 33.27; 95% CI 2.79-395.89; 
p < 0.01) and to multidrug-resistance (OR 16.15; 95% CI 
2.1-124.0; p < 0.01), but not with resistance to pyrazinamide 
(OR 2.66; 95% CI 0.29-23.57; p = 0.36). Only two patients 
had previous use of tuberculostatics and quinolones; one 
patient was previously treated with rifampin, isoniazid 
and pirazinamide and showed resistance to rifampin, 
isoniazid, pirazinamide and ethambutol. The other patient had 
previous use of prophylactic isoniazid and showed resistance 
to isoniazid, streptomycin and ethambutol.
On multivariate analysis including previous use of 
tuberculostatics, previous rifampin, isoniazid, pirazinamide, 
streptomycin, ethambutol, or quinolone use, the following 
factors were independently associated with any drug 
resistance: previous use of rifampin (p < 0.01), isoniazid 
(p < 0.01), streptomycin (p < 0.01), and quinolone use (p < 0.01).
Discussion
In our setting, tuberculosis incidence and resistance profile 
to first line anti-TB drugs was low, according to the OMS 
classification.6 Besides, comparing to data published a few 
years before, it remained stable. A previous study (1997-
2003) from our center showed that resistance to a single 
drug was observed in 12.6% of 398 patients, and MDR-TB was 
 BRAZ J INFECT DIS. 2012;16(2):142-145 145
Acknowledgements 
We would like to thank FIPE (Hospital de Clínicas de Porto 
Alegre, Brazil) for partial support of this study.
Conflict of interest
All authors declare to have no conflict of interest.
R E F E R E N C E S
 1.  Reid A, Scano F, Getahun H, et al. Towards universal 
access to HIV prevention, treatment, care, and support: the 
role of tuberculosis/HIV collaboration. Lancet Infect Dis. 
2006;6:483-495.
 2.  Donald PR, van Helden PD. The global burden of tuberculosis 
— combating drug resistance in difficult times. N Engl J Med. 
2009;23:2393-2395.
 3.  Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and 
multidrug-resistant tuberculosis – the perfect storm. JID. 
2007;196(Suppl 1). 
 4.  Lew W, Pai M, Oxlade O, et al. Initial drug resistance and 
tuberculosis treatment outcomes: systematic review and 
meta-analysis. Ann Intern Med. 2008;149:123-134. 
 5.  Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug 
resistant tuberculosis in Europe: a systematic review. Thorax. 
2006;61:158-163. 
 6.  World Health Organization. Global tuberculosis control: a 
short update to the 2009 report. World Health Organization; 
2009. 
 7.  Wolfart M, Barth AL, Willers D, et al. Mycobacterium 
tuberculosis resistance in HIV-infected patients from a tertiary 
careteaching hospital in Porto Alegre, southern Brazil. Trans 
R Soc Trop Med Hyg. 2008;102:421-425. 
 8.  Fandinho F, Kritski A, Hofer C, et al. Drug resistance patterns 
among hospitalized tuberculous patients in Rio de Janeiro, 
Brazil, 1993-1994. Mem Inst Oswaldo Cruz. 1999;94:543-547. 
 9.  Pinto WP, Hadad DJ, Silva Telles MA, et al. Tuberculosis 
and drug resistance among patients seen at an AIDS 
reference center in Sao Paulo, Brazil. Int J Infect Dis. 
2001;5:93-100. 
10.  Kliiman K, Altraja A. Predictors of extensively drug-resistant 
pulmonary tuberculosis. Ann Intern Med. 2009;150:766-775. 
11.  Vashakidze L, Salakaia A, Shubladze N, et al. Prevalence 
and risk factors for drug resistance among hospitalized 
tuberculosis patients in Georgia. Int J Tuberc Lung Dis. 
2009;13:1148-1153. 
12.  Park IN, Hong SB, Oh YM, et al. Impact of short-term 
exposure to quinolones on ofloxacin resistance in HIV-
negative patients with tuberculosis. Int J Tuberc Lung Dis. 
2007;11:319-324. 
13.  Wang JY, Lee LN, Lai HC, et al. Quinolone resistance in 
Mycobacterium tuberculosis isolates: associated genetic 
mutations and relationship to antimicrobial exposure. JAC. 
2007;59:860-865. 
14.  Long R, Chong H, Hoeppner V, et al. Empirical treatment 
of community-acquired pneumonia and the development 
of quinolone-resistant tuberculosis. Clin Infect Dis. 
2009;48:1354-1360. 
found in 2% of patients.7 Two years later our local resistant 
profile did not change, and is lower than other parts of the 
country. The prevalence of TB resistance in HIV-infected 
patients in Rio de Janeiro was 16.6% (any first-line drugs),8 
and more than 19% in São Paulo with 11.3% of multidrug 
resistance tuberculosis.9 Nonetheless, these data are from 
patients collected from a single tertiary care center and 
do not necessarily represent the resistance profile of the 
general population with TB.
In Estonia, a study from 2003 to 2005 found a strong 
association between previously treated tuberculosis and multi-
drug and extensive drug resistance.10 Also, a systematic review 
showed previous treatment as the strongest determinant of 
MDR-TB.5 In addition, age under 65 years, living outside Europe, 
male gender, and persons infected with HIV were associated 
with MDR-TB.11 
As shown in our data, other authors have demonstrated 
that previous use of quinolones was related to drug 
resistance. In the study by Park et al., previous ofloxacin 
use was not associated with ofloxacin resistance or with 
other antituberculosis drug resistance. One patient with 
previous use of levofloxacin developed ofloxacin, rifampin, 
isoniazid and pyrazinamid resistance.12 In the study by 
Wang al., the Mycobacterium tuberculosis isolates resistant 
to first-line antituberculosis drugs were more likely to have 
quinolone resistance, but they did not address a cause-effect 
relationship between previous quinolones use and first-line 
anti-TB drug resistance.13 Long et al. showed that multiple, 
but not single, quinolone prescriptions were associated with 
quinolone resistant TB. In this study, most patients who 
had received multiple quinolone prescriptions had TB with 
first-line drug resistance.14 So far, there is no evidence of 
cross-resistance between quinolones and anti-TB agents. 
The quinolones and first line TB drugs do not share similar 
mechanisms of resistance and there is a lack of data 
referring to this cause-effect relationship. However, we 
found a correlation between previous use of quinolones and 
first-line TB drugs resistance. 
Our study has some obvious limitations that could threat 
the validity of our results. This study analyzed inpatients’ 
samples from a single reference center, and due to the 
retrospective design, confounding factors could have not 
been controlled. On the other hand, despite a lack of evidence 
regarding cross-resistance, previous quinolone use could 
be assumed as a surrogate marker of first-line TB drugs 
resistance.
Conclusions
In summary, previous use of quinolones was significantly 
related to first-line anti-TB drugs resistance. The identification 
of significant associations must be accompanied by biological 
plausibility. However, it is important to validate these results 
in prospective controlled studies. Nevertheless, MDR-TB 
is a major problem worldwide, and our study suggests that 
quinolones should not be used as first-line antibiotics to treat 
pneumonia in settings were TB is endemic.
